Takero Shindo

Hiroshima, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 76 publications

Platinum TALEN-mediated nonviral gene editing facilitates clinical-scale production of cancer antigen-reactive T cells.

Platinum TALEN-mediated nonviral gene editing facilitates clinical-scale production of cancer antigen-reactive T cells.

Journal: Cytotherapy

Published: January 17, 2026

Long-read KIR genotyping reveals donor KIR/HLA polymorphisms linked to posttransplant relapse in T-cell malignancies.

Long-read KIR genotyping reveals donor KIR/HLA polymorphisms linked to posttransplant relapse in T-cell malignancies.

Journal: Blood advances

Published: November 13, 2025

Tumor Inflammation-associated Neurotoxicity Following CD19-targeted Chimeric Antigen Receptor T-cell Therapy in a Patient with High-grade B-cell Lymphoma.

Tumor Inflammation-associated Neurotoxicity Following CD19-targeted Chimeric Antigen Receptor T-cell Therapy in a Patient with High-grade B-cell Lymphoma.

Journal: Internal medicine (Tokyo, Japan)

Published: October 01, 2025

Real-world treatments and outcomes of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a Japanese claims analysis.

Real-world treatments and outcomes of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a Japanese claims analysis.

Journal: International journal of hematology

Published: August 14, 2025

The Intersection of Lynch Syndrome and Hematological Malignancies: A Rare Short Report.

The Intersection of Lynch Syndrome and Hematological Malignancies: A Rare Short Report.

Journal: EJHaem

Published: April 17, 2025

Impact of HLA Epitope Matching on Outcomes in Haploidentical HSCT With Distinct GVHD Prophylaxes.

Impact of HLA Epitope Matching on Outcomes in Haploidentical HSCT With Distinct GVHD Prophylaxes.

Journal: Transplantation

Published: February 14, 2025

Control of immune response in an iPSC-based allogeneic cell therapy clinical trial for Parkinson's disease.

Control of immune response in an iPSC-based allogeneic cell therapy clinical trial for Parkinson's disease.

Journal: Cell stem cell

Published: December 19, 2024

Acalabrutinib and Obinutuzumab for Chronic Lymphocytic Leukemia Complicated With Peripheral Neuropathy.

Acalabrutinib and Obinutuzumab for Chronic Lymphocytic Leukemia Complicated With Peripheral Neuropathy.

Journal: Cureus

Published: November 28, 2024

Upregulation of YY1/EZH2 and MLH1 as Therapeutic Targets for Adult T-Cell Leukemia/Lymphoma.

Upregulation of YY1/EZH2 and MLH1 as Therapeutic Targets for Adult T-Cell Leukemia/Lymphoma.

Journal: Cancer science

Published: October 27, 2024

Significant detrimental impact of pre-transplant mogamulizumab on the post-transplant outcome with a short interval between the last mogamulizumab and transplantation.

Significant detrimental impact of pre-transplant mogamulizumab on the post-transplant outcome with a short interval between the last mogamulizumab and transplantation.

Journal: Bone marrow transplantation

Published: September 22, 2024

Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson's disease.

Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson's disease.

Journal: Nature

Published: August 09, 2024

Tirabrutinib for CNS relapsed primary vitreoretinal lymphoma.

Tirabrutinib for CNS relapsed primary vitreoretinal lymphoma.

Journal: Annals of hematology

Published: July 16, 2024

Showing 1-12 of 76

Last Updated: 09/26/2026